
Incidence, kinetics, and risk factors of Epstein-Barr virus viremia in pediatric patients after allogeneic stem cell transplantation
- Author
- Maria Bordon Cueto De Braem (UGent) , Elizaveta Padalko (UGent) , Yves Benoit (UGent) , Catharina Dhooge (UGent) and Genevieve Laureys (UGent)
- Organization
- Abstract
- After allogeneic hematopoietic stem-cell transplantation (allo-HSCT), EBV infections can be potentially dangerous and even life threatening. We evaluated the EBV viremia in 80 consecutive allo-HSCT with quantitative EBV-PCR every 2 weeks during the first 3 months and monthly thereafter until 1 yr after allo-HSCT or until death. We found a significantly more frequent viremia in patients who had in vivo T-cell depletion in which 23 out of 51 (45%) had EBV-PCR positivity. The EBV virus load was also significantly higher in the in vivo T-cell depleted group. Three patients developed clinical symptoms of EBV-PTLD and were treated with monoclonal anti-CD20 antibodies. No EBV-driven mortality was seen in this cohort. In our opinion EBV-PCR monitoring is mandatory after allo-HSCT. Most of the patients with EBV viremia had a good evolution after tapering the immune suppression, so this should be the first-line management of pediatric patients with EBV viremia. Monoclonal anti-CD20 antibodies should be reserved for those patients with early symptoms of EBV-PTLD.
- Keywords
- Epstein-Barr virus infections, EBV-LYMPHOPROLIFERATIVE DISEASE, children, RITUXIMAB, allogeneic stem cell transplantation, SCT, DISORDERS, HYPOGAMMAGLOBULINEMIA, INTERVENTION, RECOVERY, LOAD, PCR
Downloads
-
(...).pdf
- full text
- |
- UGent only
- |
- |
- 97.62 KB
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-2963277
- MLA
- Bordon Cueto De Braem, Maria, et al. “Incidence, Kinetics, and Risk Factors of Epstein-Barr Virus Viremia in Pediatric Patients after Allogeneic Stem Cell Transplantation.” PEDIATRIC TRANSPLANTATION, vol. 16, no. 2, 2012, pp. 144–50, doi:10.1111/j.1399-3046.2011.01634.x.
- APA
- Bordon Cueto De Braem, M., Padalko, E., Benoit, Y., Dhooge, C., & Laureys, G. (2012). Incidence, kinetics, and risk factors of Epstein-Barr virus viremia in pediatric patients after allogeneic stem cell transplantation. PEDIATRIC TRANSPLANTATION, 16(2), 144–150. https://doi.org/10.1111/j.1399-3046.2011.01634.x
- Chicago author-date
- Bordon Cueto De Braem, Maria, Elizaveta Padalko, Yves Benoit, Catharina Dhooge, and Genevieve Laureys. 2012. “Incidence, Kinetics, and Risk Factors of Epstein-Barr Virus Viremia in Pediatric Patients after Allogeneic Stem Cell Transplantation.” PEDIATRIC TRANSPLANTATION 16 (2): 144–50. https://doi.org/10.1111/j.1399-3046.2011.01634.x.
- Chicago author-date (all authors)
- Bordon Cueto De Braem, Maria, Elizaveta Padalko, Yves Benoit, Catharina Dhooge, and Genevieve Laureys. 2012. “Incidence, Kinetics, and Risk Factors of Epstein-Barr Virus Viremia in Pediatric Patients after Allogeneic Stem Cell Transplantation.” PEDIATRIC TRANSPLANTATION 16 (2): 144–150. doi:10.1111/j.1399-3046.2011.01634.x.
- Vancouver
- 1.Bordon Cueto De Braem M, Padalko E, Benoit Y, Dhooge C, Laureys G. Incidence, kinetics, and risk factors of Epstein-Barr virus viremia in pediatric patients after allogeneic stem cell transplantation. PEDIATRIC TRANSPLANTATION. 2012;16(2):144–50.
- IEEE
- [1]M. Bordon Cueto De Braem, E. Padalko, Y. Benoit, C. Dhooge, and G. Laureys, “Incidence, kinetics, and risk factors of Epstein-Barr virus viremia in pediatric patients after allogeneic stem cell transplantation,” PEDIATRIC TRANSPLANTATION, vol. 16, no. 2, pp. 144–150, 2012.
@article{2963277, abstract = {{After allogeneic hematopoietic stem-cell transplantation (allo-HSCT), EBV infections can be potentially dangerous and even life threatening. We evaluated the EBV viremia in 80 consecutive allo-HSCT with quantitative EBV-PCR every 2 weeks during the first 3 months and monthly thereafter until 1 yr after allo-HSCT or until death. We found a significantly more frequent viremia in patients who had in vivo T-cell depletion in which 23 out of 51 (45%) had EBV-PCR positivity. The EBV virus load was also significantly higher in the in vivo T-cell depleted group. Three patients developed clinical symptoms of EBV-PTLD and were treated with monoclonal anti-CD20 antibodies. No EBV-driven mortality was seen in this cohort. In our opinion EBV-PCR monitoring is mandatory after allo-HSCT. Most of the patients with EBV viremia had a good evolution after tapering the immune suppression, so this should be the first-line management of pediatric patients with EBV viremia. Monoclonal anti-CD20 antibodies should be reserved for those patients with early symptoms of EBV-PTLD.}}, author = {{Bordon Cueto De Braem, Maria and Padalko, Elizaveta and Benoit, Yves and Dhooge, Catharina and Laureys, Genevieve}}, issn = {{1397-3142}}, journal = {{PEDIATRIC TRANSPLANTATION}}, keywords = {{Epstein-Barr virus infections,EBV-LYMPHOPROLIFERATIVE DISEASE,children,RITUXIMAB,allogeneic stem cell transplantation,SCT,DISORDERS,HYPOGAMMAGLOBULINEMIA,INTERVENTION,RECOVERY,LOAD,PCR}}, language = {{eng}}, number = {{2}}, pages = {{144--150}}, title = {{Incidence, kinetics, and risk factors of Epstein-Barr virus viremia in pediatric patients after allogeneic stem cell transplantation}}, url = {{http://dx.doi.org/10.1111/j.1399-3046.2011.01634.x}}, volume = {{16}}, year = {{2012}}, }
- Altmetric
- View in Altmetric
- Web of Science
- Times cited: